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ABSTRACT:
Krüppel-like factors (KLFs) comprise a highly conserved family of zinc finger 
transcription factors, that are involved in a plethora of cellular processes, ranging 
from proliferation and apoptosis to differentiation, migration and pluripotency. During 
the last few years, evidence on their role and deregulation in different human cancers 
has been emerging. This review will discuss current knowledge on Krüppel-like 
transcription in the epithelial-mesenchymal transition (EMT), invasion and metastasis, 
with a focus on epithelial cancer biology and the extensive interface with pluripotency. 
Furthermore, as KLFs are able to mediate different outcomes, important influences of 
the cellular and microenvironmental context will be highlighted. Finally, we attempt 
to integrate diverse findings on KLF functions in EMT and stem cell biology to fit in the 
current model of cellular plasticity as a tool for successful metastatic dissemination.  
1. The SP/KLF-family of transcription factors
Specificity proteins (SP) and Krüppel-like factors 
(KLFs) are collectively referred to as the SP1-like/KLF 
or SP/KLF family of transcription factors. SP1 was first 
identified in the early 1980s as a protein that was able 
to bind GC- and related GT-rich regions or CACCC 
elements in the SV40 promoter and, therefore, could 
serve as a transcriptional regulator [1]. Several SP-like 
factors have been found since and, to date, this subfamily 
contains 9 members (SP1 – 9). The DNA-binding region 
of SPs consists of three highly conserved Cys2/His2 zinc 
fingers, localized near the C-terminal end of the protein 
[2]. The interfinger linking sequences, called “H/C links”, 
containing a stretch of seven amino acids also show a 
high degree of conservation (TGE(R/K)P(Y/F)X) within 
the family and between species [3]. The presence of this 
typical structure in the Drosophila melanogaster gap gene 
Krüppel [4] has given rise to the association with the 
Krüppel-like part of this transcription factor family [5]. 
The first mammalian homologue to Drosophila 
Krüppel was discovered in a murine erythroleukemic cell 
line [6] and named E-KLF (Erythroid Krüppel-like factor, 
KLF1). This factor was shown to trans-activate ß-globin 
expression by binding the CACCC element within its 
promoter [7]. Loss-of-function studies demonstrated that 
homozygous E-KLF-/- mice developed fatal ß-thalassaemia 
during early fetal liver erythropoiesis [8] Numerous 
closely related human proteins have been identified since 
and collectively named Krüppel-like factors (KLFs), 
preceded by an index letter of the tissue or origin of 
enriched expression (X-KLF, Table 1 and Fig 1a).
The homology between SP/KLF proteins is mainly 
restricted to the zinc finger and linker domains, situated 
at the C-terminal, and underlines the importance of this 
structure in transcription biology (Fig 1b). The major 
difference distinguishing SPs from KLFs is the absence 
of a Buttonhead box CXCPXC preceding the triple zinc 
finger region in the latter [9]. Furthermore, several SP/
KLFs (KLF1, 2, 4, 9, 13, 16) share a nuclear localization 
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signal (NLS), necessary for post-translational transport 
towards the nucleus [10]. More variability exists within 
the N-terminal regions of KLFs, containing both activator 
and/or repressor domains that interact with specific 
coactivators and -repressors, providing unique functions 
to each family member.    
As of currently, the KLF family of transcription 
factors comprises 17 identified members (KLF1 - 17) 
with diverse regulatory roles in differentiation, survival, 
proliferation and development. To avoid confusion 
because of alternative names, a straightforward SP/KLF 
nomenclature has been generated by the Human Genome 
Organization Gene Nomenclature Committee (HGNC, 
www.genenames.org) in which all SPs and KLFs have 
been numbered sequentially in order of their discovery 
(Table 1) [5,9]. This nomenclature will be followed 
throughout this review.
For reasons of conciseness, this review will further 
handle current knowledge on the KLF subfamily within 
the epithelial-mesenchymal transition (EMT), carcinoma 
progression and metastasis, added with uncovered roles 
in induced pluripotency and self renewal biology. More 
extended structural and functional information regarding 
SPs can be found in previous reviews [11,12].
Table 1: Classification and summary of the SP/KLF family in humans. 
HGNC Alias Gene accession # UniProt KB entry #
# amino 
acids
Molecular 
weight (kDa)
SP1 TFSP1 BC062539 P08047 785 80.7
SP2 KIAA0048 NM_003110 Q02086 613 64.9
SP3 SPR-2 AY070137 Q02447 781 81.9
SP4
SPR-1,HF1B, MGC130008, 
MGC130009
NM_003112 Q02446 784 82
SP5 AB096175 Q6BEB4 398 42
SP7 OSX BC113613 Q8TDD2 431 45
SP8 BC038669 Q8IXZ3 490 48.7
SP9 ZNF990 NM_001145250 P0CG40 484 48.9
KLF1 E-KLF JX877554 Q13351 362 38.2
KLF2 L-KLF EF078888 Q9Y5W3 355 37.4
KLF3 B-KLF, TEF-2 NM_016531 P57682 345 38.8
KLF4 G-KLF, EZF DQ658241 O43474 513 54
KLF5 I-KLF, C-KLF, BTEB2 AF287272 Q13887 457 50.8
KLF6
BCD1, COBEP, CBPB, ST12, 
GBF
AF284036 Q99612 283 31.9
KLF7 U-KLF O75840 302 33.4
KLF8 BKLF3, ZNF741 NM_007250 O95600 359 39.3
KLF9 BTEB, BTEB1 NM_001206 Q13886 244 27.2
KLF10 TIEG, TIEG1, EGRα NM_005655 Q13118 480 52.6
KLF11 F-KLF, TIEG2, MODY7 O14901 512 55.1
KLF12 AP2rep, HSPC122 Q9Y4X4 402 44.2
KLF13 BTEB3, NSLP1, RFLAT-1 NM_015995 Q9Y2Y9 288 31.2
KLF14 BTEB5, SP6, EPFN DQ534757 Q8TD94 323 33.1
KLF15 K-KLF NM_014079 Q9UIH9 416 44
KLF16 BTEB4, NSLP2, DRRF NM_031918 Q9BXK1 252 25.4
KLF17 ZNF393 NM_173484 Q5JT82 389 42.6
Abbreviations: AP2rep AP2 repressor, B basic, BCD B-cell derived protein, BTEB basic transcription element binding, C colon, COBEP core 
promoter element binding protein, CPBP core promoter binding protein, DRRF dopamine receptor regulating factor, E erythroid, EGRα early growth 
response gene α, EPFN epiprofin, EZF epithelial zinc finger, F embryonic/fetal ß-like globin gene-activating, G gut, GBF GC-rich binding factor, I 
intestinal, K kidney, L lung, MODY7 maturity-onset diabetes of the young 7, NSLP Novel SP1-Like Protein,  OSX osterix, RFLAT RANTES factor 
of late activated T-lymphocytes, SP specificity protein / SV40-promoter protein, ST suppressor of tumorigenicity, TFSP transcription factor SP, SPR 
SP1-related factor, TEF transcriptional enhancer factor, TIEG TGFß-inducible early gene, U ubiquitous, Z(N)F zinc finger
Sources: HUGO Gene Nomenclature Committee (www.genenames.org) and [9]. Protein molecular weights were retrieved from The Human Protein 
Atlas (www.proteinatlas.org) [149].
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2. KLFs in EMT and invasion
2.1 EMT
EMT constitutes a transdifferentiation program 
whereby cells shift from an apical-basal to front-back 
polarity. The existence of EMT was first established 
within embryonic development [13]. This transition 
characteristically involves the loss of adherens junctions, 
typically E-cadherin (CDH1), that guarantee the 
lateral cell-cell contacts in epithelial layers. In parallel, 
desmosomes, cytoplasmic ß-catenin (CTNNB1), 
tight junctions (claudins, occludins and ZO-1/TJP1) 
and epithelial cytokeratins (CK18/KRT18) become 
downregulated. On the other hand, the expression of 
vimentin (VIM), part of the mesenchymal intermediate 
cytoskeleton, is induced together with N-cadherin 
(CDH2). In addition, the increased deposition of cellular 
fibronectin (FN1) and the subsequent activation of 
integrins facilitate cell migration and extracellular matrix 
(ECM) invasion [14,15]. 
EMT provides a mechanism that enables cancer 
cells to invade individually into the surrounding stroma. 
In addition, the morphotype switch has been demonstrated 
to be reversible, with the existence of mesenchymal-
epithelial transition (MET) as an inverse mechanism, 
necessary during metastatic colonization [13,16].
Several master transcription factors have been 
identified in conferring EMT (Fig 2): Snail (SNAI1) 
[17,18], Slug (SNAI2) [19], Twist (TWIST1) [20], ZEB1/
δEF1 (ZEB1) [21,22], ZEB2/SIP1 (ZEB2) [23], E12/E47 
(TCF3) [24], Hey1 (HEY1) [25] and HMGA2 (HMGA2) 
[26]. Most of these factors primarily share the direct 
repression of CDH1 through binding of E-boxes in its 
promoter. 
KLF8 is a potent inducer of EMT through CDH1 
repression [27]. KLF8 was shown to directly bind to a 
GT box within the CDH1 promoter, hereby uncovering 
the presence of another consensus element that is targeted 
by the distinct family of KLF zinc finger transcription 
factors, next to the known triple E-box motif. As the DNA 
binding zinc finger regions are highly conserved between 
KLFs, similar target sequences may be recognized by 
different members. The variable nature of the N-terminal 
domains, on the other hand, may give rise to opposite 
trans-regulatory effects. Despite the ambiguous reporting 
on the tumor suppressing yet oncogenic roles of KLF4 
in epithelial cancer biology (see invasion and metastasis 
and Fig 1), its function in EMT/MET has increasingly 
become clear. In cancer-related EMT as well as in EMT 
processes that contribute to the reprogramming route, 
KLF4 is a potent inducer of epithelial differentiation and 
antagonizes the switch to a mesenchymal phenotype. 
Transcriptional regulation by KLF4 increases the 
expression of CDH1 and forces adult human fibroblasts 
into an epithelial state that proved a prerequisite for 
successful reprogramming to pluripotency [28]. Indeed, 
in MCF-10A normal mammary epithelium, KLF4 was 
shown to activate CDH1 transcription through binding of 
CACCC consensus sequences in the proximal promoter of 
the CDH1 gene [29]. KLF4 silencing resulted in a cadherin 
switch (loss of CDH1 with concomitant gain of CDH2 
[30]) and a decrease of cytosolic ß-catenin. Consequently, 
overexpression of KLF4 in the metastatic MDA-MB-231 
breast cancer cell line dramatically increased CDH1 
and KRT18 expression, indicating the restoration of 
an epithelial phenotype and loss of metastasis. The 
mechanism of EMT impairment by KLF4 can be explained 
by its repressive action on the EMT transcription factors 
SNAI1 [31] and SNAI2 [28,32]. Conversely, in EMT-
induced colon cancer cells, Snail was shown to repress 
the expression of KLF4 [33]. This finding fits within a 
previously described role of KLF4 in specific aspects of 
epithelial cell differentiation [34] and provides a rationale 
for loss of this factor in cancer. Direct binding sites for 
KLF4 have been detected in the promoter sequences of 
vimentin (VIM), VEGF-A (VEGFA), endothelin-1 (EDN1) 
and JNK-1 (MAPK8), next to E-cadherin (CDH1), 
N-cadherin (CDH2) and CTNNB1, indicating a central role 
for KLF4 within the EMT program [35]. These findings 
can at least partly explain the downregulation of KLF4 as 
reported for several epithelial cancer types and the inverse 
correlation of KLF4 expression with clinical outcome 
[32,36,37]. 
Nevertheless, in HepG2 hepatocellular carcinoma 
and Madin-Darby canine kidney (MDCK) cells, a direct 
KLF4-mediated downregulation of CDH1 was observed, 
downstream of hepatocyte growth factor (HGF, also 
known as scatter factor/SF)-induced cell scattering (Fig 
2). Moreover, KLF4 expression was activated by early 
growth response-1 (EGR1) under stimulation of HGF and 
sustained itself through a transcriptional auto-activation 
loop [38]. HGF-mediated cell scattering is largely 
dependent on SNAI1 activation, downstream of HGF 
signaling [39], implying an important EMT transcription 
factor in this process. These apparent contradictions might 
be explained using a contextual view on these cellular 
events. KLF4 is able to act as an activator or repressor of 
downstream genes, depending on the availability of co-
activators or co-repressors in its environment. 
KLF5 activates CDH1 expression and 
downregulation of VIM in non-small cell lung cancer 
cells [40]. Both KLF4 and KLF5 show competition for 
promoter binding sites with antagonizing effects regarding 
proliferation [41]. In intestinal cells, KLF4 represents a 
marker for differentiated villus cells whereas KLF5 
positively regulates proliferation in the crypt cells [41]. 
The latter has been confirmed by providing evidence 
of increased cyclin-D1 (CCND1) transcription, colony 
formation and cell growth in normal ileal cells (IEC-
18) and Immorto-Min Colon Epithelial (IMCE) cells 
overexpressing KLF5 [42]. Contrastingly however, the 
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same group demonstrated inhibition of proliferation in 
KLF5-overexpressing DLD-1 colon adenocarcinoma 
cells. Interestingly, in the context of oncogenic Ras, 
KLF5 became significantly downregulated by at least two 
mechanisms, namely reduced mRNA transcription and 
proteasomal degradation. Reduced expression of KLF5 
in intestinal cancer when compared to normal epithelium 
could also indirectly promote EMT by relieving the 
promotional activity upon the CDH1 promoter. 
KLF6, originally identified as a tumor suppressor in 
prostate carcinoma [43], also activates the CDH1 promoter 
[44]. The tumor suppressor function of KLF6 was 
further demonstrated in hepatic [45] and gastric cancer 
[46,47] and linked to a role in cellular differentiation. 
Several mechanisms leading to KLF6 loss have been 
described, including promoter hypermethylation [48], 
somatic mutations and loss of heterozygosity in prostate 
[43], gastric [47] and ovarian cancer [49]. Interestingly, 
Fig 1: a). Phylogenetic tree resulting from a molecular phylogenetic analysis, based on the protein sequences of all human SP/KLF 
members using the Mega5 (v5.1) built-in Maximum Likelihood method and Nearest Neighbor-Joining algorithm [150]. b). Amino acid 
sequence alignment of the zinc finger C-terminal region of all known SPs and KLFs, as determined by ClustalW using Mega5 (v5.1) 
software. Indicated are the three separate zinc finger sequences (grey boxes, ZnF) and conserved amino acids (green).
Fig 1
a
b
SP1  CPYCKDSEGRGSG--DPGKKKQHICHIQGCGKVYGKTSHLRAHLRWHTGERPFMCTWSYCGKRFTRSDELQRHKRTHTGEKKFACPECPKRFMRSDHLSKHIKTHQNKKGGPGVALSVG-
SP2  CPNCKDGEKRSG----EQGKKKHVCHIPDCGKTFRKTSLLRAHVRLHTGERPFVCNWFFCGKRFTRSDELQRHARTHTGDKRFECAQCQKRFMRSDHLTKHYKTHLVTKNL---------
SP3  CPNCKEGGGR-GT--NLGKKKQHICHIPGCGKVYGKTSHLRAHLRWHSGERPFVCNWMYCGKRFTRSDELQRHRRTHTGEKKFVCPECSKRFMRSDHLAKHIKTHQNKKGIHSSSTVLAS
SP4  CPNCREGEGRGSN--EPGKKKQHICHIEGCGKVYGKTSHLRAHLRWHTGERPFICNWMFCGKRFTRSDELQRHRRTHTGEKRFECPECSKRFMRSDHLSKHVKTHQNKKGGGTALAIVT-
SP5  CPNCQAAGGAPEA--EPGKKKQHVCHVPGCGKVYGKTSHLKAHLRWHTGERPFVCNWLFCGKSFTRSDELQRHLRTHTGEKRFACPECGKRFMRSDHLAKHVKTHQNKKLKVAEAGVKRE
SP7  CPNCQELERLGAAAAGLRKKPIHSCHIPGCGKVYGKASHLKAHLRWHTGERPFVCNWLFCGKRFTRSDELERHVRTHTREKKFTCLLCSKRFTRSDHLSKHQRTHGEPGPGPPPSGPKEL
SP8  CPNCQEAERLGPAGASLRRKGLHSCHIPGCGKVYGKTSHLKAHLRWHTGERPFVCNWLFCGKRFTRSDELQRHLRTHTGEKRFACPVCNKRFMRSDHLSKHVKTHSGGGGGGGSAGSGSG
SP9  CPNCQEAERLGPAGASLRRKGLHSCHIPGCGKVYGKTSHLKAHLRWHTGERPFVCNWLFCGKRFTRSDELQRHLRTHTGEKRFACPVCNKRFMRSDHLSKHIKTHNGGGGG---------
KLF1  VIAETAPSKRGRRSWARKRQAAHTCAHPGCGKSYTKSSHLKAHLRTHTGEKPYACTWEGCGWRFARSDELTRHYRKHTGQRPFRCQLCPRAFSRSDHLALHMKRHL--------------
KLF2  ----EAKPKRGRRSWPRKRTATHTCSYAGCGKTYTKSSHLKAHLRTHTGEKPYHCNWDGCGWKFARSDELTRHYRKHTGHRPFQCHLCDRAFSRSDHLALHMKRHM--------------
KLF3  ---PGKRPLPVESPDTQRKRRIHRCDYDGCNKVYTKSSHLKAHRRTHTGEKPYKCTWEGCTWKFARSDELTRHFRKHTGIKPFQCPDCDRSFSRSDHLALHRKRHMLV------------
KLF4  CMPEEPKPKRGRRSWPRKRTATHTCDYAGCGKTYTKSSHLKAHLRTHTGEKPYHCDWDGCGWKFARSDELTRHYRKHTGHRPFQCQKCDRAFSRSDHLALHMKRHF--------------
KLF5  SQNIQPVRYNRRSNPDLEKRRIHYCDYPGCTKVYTKSSHLKAHLRTHTGEKPYKCTWEGCDWRFARSDELTRHYRKHTGAKPFQCGVCNRSFSRSDHLALHMKRHQN-------------
KLF6  -TSGKPGDKGNGDASPDGRRRVHRCHFNGCRKVYTKSSHLKAHQRTHTGEKPYRCSWEGCEWRFARSDELTRHFRKHTGAKPFKCSHCDRCFSRSDHLALHMKRHL--------------
KLF7  -QSDSDQGGLGAEACPENKKRVHRCQFNGCRKVYTKSSHLKAHQRTHTGEKPYKCSWEGCEWRFARSDELTRHYRKHTGAKPFKCNHCDRCFSRSDHLALHMKRHI--------------
KLF8  -----MAQMQGEESLDLKRRRIHQCDFAGCSKVYTKSSHLKAHRRIHTGEKPYKCTWDGCSWKFARSDELTRHFRKHTGIKPFRCTDCNRSFSRSDHLSLHRRRHDTM------------
KLF9  ----LHPGVAAKG--KHASEKRHKCPYSGCGKVYGKSSHLKAHYRVHTGERPFPCTWPDCLKKFSRSDELTRHYRTHTGEKQFRCPLCEKRFMRSDHLTKHARRHTEFHPSMIKRSKKAL
KLF10  ----SAAKVTPQI--DSSRIRSHICSHPGCGKTYFKSSHLKAHTRTHTGEKPFSCSWKGCERRFARSDELSRHRRTHTGEKKFACPMCDRRFMRSDHLTKHARRHLSAKKLPN-WQMEV-
KLF11  ----SSQNCVPQV--DFSRRRNYVCSFPGCRKTYFKSSHLKAHLRTHTGEKPFNCSWDGCDKKFARSDELSRHRRTHTGEKKFVCPVCDRRFMRSDHLTKHARRHMTTKKIPG-WQAEV-
KLF12  -SIESTRRQRRSESPDSRKRRIHRCDFEGCNKVYTKSSHLKAHRRTHTGEKPYKCTWEGCTWKFARSDELTRHYRKHTGVKPFKCADCDRSFSRSDHLALHRRRHMLV------------
KLF13  ----VRRGRSRAD--LESPQRKHKCHYAGCEKVYGKSSHLKAHLRTHTGERPFACSWQDCNKKFARSDELARHYRTHTGEKKFSCPICEKRFMRSDHLTKHARRHANFHPGMLQRRGGGS
KLF14  ----ADQAPRRRS--VTPAAKRHQCPFPGCTKAYYKSSHLKSHQRTHTGERPFSCDWLDCDKKFTRSDELARHYRTHTGEKRFSCPLCPKQFSRSDHLTKHARRHPTYHPDMIEYRGRRR
KLF15  --------KF-PKNPAAELIKMHKCTFPGCSKMYTKSSHLKAHLRRHTGEKPFACTWPGCGWRFSRSDELSRHRRSHSGVKPYQCPVCEKKFARSDHLSKHIKVHRFPRSSRSVRSVN--
KLF16  ------------A--PSAAAKSHRCPFPDCAKAYYKSSHLKSHLRTHTGERPFACDWQGCDKKFARSDELARHHRTHTGEKRFSCPLCSKRFTRSDHLAKHARRHPGFHPDLLRRPGARS
KLF17  -KNSRPQEGTGRR--GSSEARPYCCNYENCGKAYTKRSHLVSHQRKHTGERPYSCNWESCSWSFFRSDELRRHMRVHTRYRPYKCDQCSREFMRSDHLKQHQKTHRPGPSDPQANNNNG-
ZnF 1 ZnF 2 ZnF 3
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an alternative mechanism to downregulate KLF6 was 
found to involve the generation of three splice variants 
(SV1-3) with antagonistic effects on the wild type KLF6 
tumor suppressor function [50]. KLF6-SV1, one of these 
splice variants, is able to drive breast cancer cells into an 
EMT-like phenotype, with loss of CDH1 and increased 
expression of CDH2 and FN1 [51]. This was associated 
with enhanced metastatic potential, however without 
significant morphological changes. Expression of KLF6-
SV1 was found to indicate poor prognosis in several 
epithelial cancer types, including breast cancer [51], 
prostate cancer [52] and lung cancer [53]. Primordial 
findings on KLF6-SV2 point in a similar direction [45]. 
The origin of this deregulated splicing activity was traced 
to a germline single nucleotide polymorphism (SNP) in 
the KLF6 allele, generating a novel binding site for the 
SRFS5/SRp40 splicing factor [50]. HGF-dependent 
phosphorylation of Akt potentiates KLF6-SV1 signaling 
through subsequent inactivation of the splicing regulators 
SRSF3 and SRSF1 [54] (Fig 2). 
In breast cancer, KLF17 was identified as a 
metastasis suppressor, counteracting EMT in the 
168FARN murine breast cancer cell line, normal murine 
(nMuMG) and human (HMLE) breast epithelium [55]. 
Knockdown of KLF17 significantly reduced CDH1, 
TJP1 and CTNNB1 expression with concomitant increase 
of CDH2, VIM and FN1. In a cohort of human breast 
cancers, KLF17 was found to be decreased in lymph node 
positive when compared to lymph node negative tumors, 
hereby indicating a prognostic value. The authors further 
identified inhibitor-of-differentiation protein ID1 as a 
pro-metastatic regulator downstream of KLF17, which 
becomes expressed in breast cancers due to loss of its 
repressor (Fig 2). Indeed, an inverse correlation between 
KLF17 and ID1 was noted, specifically high KLF17 – 
low ID1 and low KLF17 – high ID1 in node negative 
and node positive breast tumors respectively. ID factors 
(ID1 – 3) are helix-loop-helix (HLH) transcription factors 
lacking a basic domain and unable to bind cognate DNA 
sequences. They act as dominant-negative regulators of 
the basic HLH transcription factor E47 [19,56]. E47 is an 
EMT promoting transcription factor capable of directly 
repressing CDH1 [24]. On a transient level, the formation 
of a complex with ID1 inhibits E47 from binding the 
CDH1 proximal promoter sequence, hereby switching on 
E-cadherin expression. However, introduction of ID1 in 
E47-induced mesenchymal MDCK cells was insufficient 
to restore E-cadherin transcription or an epithelial 
phenotype. Moreover, ID1 expression maintains a stable 
EMT phenotype and preserves cell viability [57]. The 
versatility of ID proteins is illustrated by their crucial role 
in early-phase metastatic colonization of the lung [58]. 
Associations between loss of KLF17 and reduced 
survival have been reported for lung and hepatic cancer 
[59,60]. In HepG2 hepatic cancer cells, KLF17 was found 
to be under post-transcriptional regulation by miR-9, 
implying an oncogenic and pro-metastatic role for this 
miR through repression of KLF17 [61].
2.2 TGFß-induced EMT
Epithelial cells can be driven to EMT under the 
influence of signaling events resulting from upstream 
extracellular cues (Fig 3). Transforming growth factor 
ß-1 (TGFß1/TGFB1) is known to drive cells towards 
a mesenchymal state through smad2/3-dependent 
transcription of SNAI1 [62,63]. Additionally, HMGA2 and 
Hey1 have been identified acting downstream of smad2/3 
and similarly blocking CDH1 expression [25,26].  In a 
mouse model of progressive prostate cancer (Pten/TP53 
null) with stem cell and EMT characteristics, TGFß-
induced EMT mainly acted through SNAI2 and to a lesser 
extent through SNAI1 [64] (Fig 3). In this setting, KLF4 
inhibits TGFß-driven EMT by directly repressing SNAI2. 
KLF4 may sustain a positive feedback loop involving 
TGFß ligand and receptors through binding of GC-boxes 
in the proximal promoters, as shown in vascular smooth 
muscle cells (VSMC) [65]. A similar mechanism had 
previously been demonstrated for KLF6 [66].
Given the reciprocal repression between KLF4 
and SNAI2 [64], the final output generated by TGFß, be 
it differentiation or EMT, could be determined by the 
intracellular balance KLF4/SNAI2. When other channels 
including signals from the surrounding microenvironment 
trigger SNAI2 in excess to KLF4, EMT through TGFß-
signaling could become the dominant process, sustained 
by KLF4-dependent positive feedback signaling. 
KLF8, a potent EMT-regulator, is induced by TGFß1 
and acts as an indispensable player in the TGFß-mediated 
EMT in gastric cancer cells [67]. Elimination of KLF8 
led to attenuation of EMT and inhibition of the associated 
capacity of migration and invasion. 
Two members of the KLF family, currently known 
as KLF10 and KLF11, are deeply embedded in TGFß 
signaling and have originally been named thereafter, 
respectively TGFß inducible early gene 1 (TIEG1) 
and 2 (TIEG2) (Table 1). Initially described as directly 
regulated by TGFß1, KLF10 [68] and KLF11 [69] provide 
supporting actions in the TGFß signaling pathway, 
exerting anti-proliferative and pro-apoptotic effects in 
epithelial cells. Both factors show a strong structural 
similarity, specifically within the zinc finger regions (91%, 
[69]). In PANC-1, MIA Paca2 and Colo357 pancreatic 
adenocarcinoma cells, KLF11 was found to sustain TGFß 
signaling both by terminating the inhibitory smad7 loop 
and through activation of smad3 [70,71]. Abrogating 
effects on smad7 have also been demonstrated for KLF10 
in hepatic and breast cancer cells [72]. Phosphorylation of 
KLF11 by MAPK in pancreatic cancer cells abrogates the 
inhibition of smad7, leading to decreased TGFß-mediated 
growth inhibition [70]. A transcriptomic screen in TGFß- 
and EGF-stimulated kidney proximal tubular cells for 
cis-regulatory elements in the differentially expressed 
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gene pool identified, among others, the KLF-targeted 
GC-boxes, and KLF10 as a principal factor in the EMT-
program, mediated by TGFß1 [73]. In agreement, KLF10 
protein expression correlated inversely with disease 
stage in a collection of 95 tissue samples of pancreatic 
adenocarcinoma and independently predicted progression-
free and overall survival in pancreatic cancer [74].
2.3 Invasion and metastasis
Local tissue invasion marks the first step of 
carcinoma progression towards the systemic dissemination 
of cancer cells and metastatic colonization of distant 
organs, a multi-step process named the invasion-metastasis 
cascade [75-77]. Next to important roles of KLFs in cell 
cycle-associated regulation of proliferation (reviewed 
in [78]), influences on the progression of epithelial 
cancers towards invasive and metastatic states have been 
described, often with effects overlapping both fields. 
This section will describe current knowledge of KLFs in 
invasiveness pathways, apart from direct associations with 
EMT processes. In addition, upstream triggering events 
and potential roles of KLFs in metastatic dissemination of 
Fig 2: Involvement of different KLFs in the molecular circuitry of EMT and invasion in a single cell and interaction 
with a recruited myeloid-derived suppressor cell (MDSC). Upper and lower half of the main image represent epithelial and 
mesenchymal states respectively. Arrows and perpendicular symbols indicate promoting and inhibitory interactions respectively. Dotted 
arrows indicate pro-invasive interactions of KLF4 and KLF5. Boxes: KLF (blue), EMT master transcription factors (red), pro-metastatic 
factors (deep red), genes (yellow), kinase (green). Filled circles represent different secreted chemokines/growth factors, as indicated.
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epithelial cancer cells will be discussed.
Within this scope however, several EMT-
modulating KLFs regulate invasion. KLF4 has yielded 
ambiguous results regarding its oncogenic yet tumor 
suppressing role (Fig 4). Initially, KLF4 was identified 
as a transforming oncogene in oral squamous epithelia 
[79] and subsequently, increased expression of KLF4 
was found in ductal carcinoma in situ of the breast and 
invasive breast cancers when compared to normal breast 
epithelium [80]. KLF4 was a marker of terminally 
differentiated epithelial cells that became deregulated in 
dysplastic epithelium. Alternatively, KLF4 transcription 
was essential in the maintenance of a breast cancer 
stem cell (CSC) population [81]. Knockdown of KLF4 
in the MCF-7 and MDA-MB-231 breast cancer cell 
lines drastically decreased the proportional number 
of CSC-like cells as defined by ALDH1 expression, 
side population and in vitro mammosphere formation 
capacity. Furthermore, downregulation of KLF4 inhibited 
breast cancer cell migration and invasion through Notch 
(NOTCH1)-mediated activity. In addition, the same group 
recently revealed a correlation between KLF4 expression 
and production of the C-X-C motif chemokine CXCL5 
(CXCL5) by primary cancer cells [82]. Chemotactic 
CXCL5 stimuli recruit C-X-C motif chemokine receptor 
(CXCR2)-positive myeloid-derived suppressor cells 
(MDSC) to the primary tumor. Interestingly, MDSCs 
residing at the invasive tumor front express high levels 
of TGFB1, further leading to increased production of 
CXCL5 in TGFBR2-deficient primary breast cancer cells 
[83]. Although the link between defective TGFß-signaling 
and CXCL5 expression remains elusive, this mechanism 
is able to contribute to the chemotactic recruitment of 
MDSCs. Moreover, enhanced production of CXCL5 
by cancer cells gives rise to the systemic secretion of 
granulocyte/monocyte colony stimulating factor (GM-
CSF), a cytokine that contributes to the maintenance of 
the MDSC pool in the bone marrow. These results may, 
in part, explain the decreased in vivo tumorigenicity and 
reduced occurrence of pulmonary metastases in a BALB/c 
mouse model, orthotopically inoculated with stable Klf4 
knockdown 4T1 murine breast cancer cells. The outcome 
of early-stage breast cancer patients, defined as death by 
breast cancer, was linked to the immunohistochemical 
staining pattern of KLF4 in their primary tumor. Strong 
nuclear and low cytoplasmic presence of KLF4 was 
highly indicative for poor prognosis [84]. Additionally, in 
squamous cell carcinoma of the head and neck (HNSCC), 
persistent expression of KLF4 correlated with poor 
prognosis, specifically in patients with advanced disease 
[85]. On a cell line level, ectopic overexpression of KLF4 
increased the tumorigenicity, migration and invasion of 
Fig 3: Involvement of KLFs in TGFß-induced EMT. Blue: KLF, red: EMT master transcription factors, yellow: genes. Red arrow 
indicates positive feedback mechanism.
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HNSCC cells. Corroborating evidence in the CSC domain 
of breast cancer was established in a study of cancer cell 
dissemination to the brain [86]. The authors found that, 
in a mammary CSC population defined as being CD44+, 
CD24- and EpCAM+, successful invasion and colonization 
of brain tissue correlated with high expression of KLF4 
and loss of a microRNA, miR-7, that targets KLF4 mRNA. 
This was opposed to CSCs metastasizing to bone, where 
KLF4 was expressed at lower levels. In metastatic brain 
lesions from patients, KLF4 and miR-7 expression were 
shown to correlate inversely, indicating a role for KLF4 
transcriptional activity in the establishment of lesions in 
the brain parenchyma. Interestingly, 9 out of a set of 17 
genes previously identified as correlated with brain relapse 
[87] contain putative binding sites for KLF4.  
These findings, related to both tumorigenicity and 
invasive behavior, are in sharp contrast with other reports 
on KLF4 function, specifically within the EMT framework 
as discussed above. Yori and colleagues have extensively 
described an inverse correlation between expression of 
KLF4 and invasiveness, mechanistically based on CDH1 
induction and thus in an EMT context [31]. MCF-10A 
normal mammary epithelium showed increased migration 
after knockdown of KLF4. In specimens of lung, gastric 
and prostate cancer, KLF4 also demonstrated decreased 
levels of expression when compared with normal tissue 
counterparts [37,88-92]. Restoration of KLF4 expression 
in vitro impaired migration and invasion of prostate cancer 
cells [37]. In the context of epithelial differentiation, 
the authors have identified the cell cycle inhibitor 
p27KIP1 (CDKN1B) as a target of KLF4, through which 
proliferation of pancreatic cancer cells was blocked [93]. 
KLF4-mediated G1/S cell cycle arrest was previously 
shown to imply activation of p21CIP1 (CDKN1A) [94]. 
However, loss of KLF4 also proved to be stimulating 
invasion, independent of CDKN1B, by the increased 
deposition of secreted protein acidic and rich in cysteine 
(SPARC, also known as osteonectin) [95]. The involvement 
of SPARC, a small calcium-binding glycoprotein that 
modifies cell-matrix adhesion, was already shown in 
breast cancer and melanoma progression due to its ability 
to induce MMP2 and SNAI1 and repress CDH1, hereby 
promoting ECM invasion and EMT [96,97]. These 
results coincide with the theory of KLF4 as a suppressor 
of EMT and invasion. The antagonistic effect of KLF4 
on tumorigenicity and disease progression was further 
demonstrated in colorectal carcinoma (CRC). IFITM3, an 
interferon-inducible gene overexpressed in CRC [98], is 
directly repressed by KLF4  [99]. Also recently, repression 
of KLF4 by the cell polarity protein Numb-like (Numbl/
NUMBL) was reported from knockdown experiments in 
the A549 lung cancer cell line. Downregulation of miR-
296 causes aberrant expression of its target NUMBL 
leading to reduced KLF4-expression and increased random 
cell migration, invasion and in vivo metastasis [100]. This 
mechanism may be more general since loss of miR-296 is 
described in several cancers [101]. Another microRNA, 
miR-10b, had been associated with metastasis by directly 
targeting KLF4 [102] or indirectly inducing the expression 
of RHOC, a prominent pro-metastatic gene [103]. 
In prostate cancer, KLF5 was found to become 
expressed downstream of androgen receptor (AR) 
signaling. The chemokine receptor CXCR4, a direct 
transcriptional target of KLF5, is subsequently activated 
and binding of its ligand CXCL12 (CXCL12, also known 
as SDF-1α) underlies the preferential chemotactic 
migration of prostate cancer cells to organ sites with 
elevated levels of CXCL12, for example bone [104,105]. 
Furthermore, from a study of keratinocyte migration, it 
is reported that KLF5 activates the expression of cell-
division-cycle 42 (CDC42), myosin light chain (MYL12B) 
and their upstream regulator integrin-linked kinase (ILK), 
hereby directly driving cell migration [106]. However, 
in esophageal cancer cells, KLF5 inhibited proliferation 
and invasive behavior [107]. This is in agreement with 
the more recently identified association between siRNA-
mediated loss of KLF5 and increased expression of CDH1 
in A549 lung cancer cells [40]. Similar to KLF4, KLF5 
seems to act in a context-dependent fashion, partially 
determined by the genetic background (Fig 4).
KLF8 activates invasion in cooperation with focal 
adhesion kinase (FAK) by increased transcription of 
matrix metalloproteinase-14 (MMP14, also known as 
MT1-MMP) in gastric cancer cells (Fig 2). In parallel, 
nuclear transportation of ß-catenin and expression of T-cell 
factor 1 (TCF1), participate in the initiation of MMP14 
transcription, indirectly effectuated by KLF8 [108]. In 
addition, KLF8 directly activated MMP9 expression [109]. 
Conversely, knockdown of KLF8 drastically inhibited 
lung metastasis in nude mice. In human breast and gastric 
cancer, overexpression of KLF8 has been shown to predict 
poor prognosis [109,110]. Similar conclusions resulted 
from a study in hepatocellular carcinoma, attributing a 
pro-invasive role to KLF8, conferring early relapse in 
human HCC [111].
Emerging data, although still limited, have identified 
KLF9 as a marker of differentiation in glioblastoma 
neurosphere cells. Knockdown of KLF9 was sufficient 
to rescue differentiating neurosphere cells as exposed 
to retinoic acid [112]. Current knowledge points toward 
a regulatory role of KLF9 in the proliferation and 
differentiation of diverse cell types [113,114]. KLF10 
is known as a supportive player in the TGFβ signaling 
cascade and is able to initiate apoptosis [115]. Next to 
its role in TGFβ-mediated EMT, KLF10 repressed the 
EGFR gene through potential binding sites in its proximal 
promoter. Reduced expression of KLF10, as reported 
for breast and pancreatic cancer [74,116], can promote 
invasive and metastatic behaviour by enhancing EGFR 
expression [117]. This may be considered in contrast with 
its supporting activity in TGFß-induced EMT, however 
depletion of KLF10 may be substituted by KLF11, which 
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exerts identical effects on smad proteins. In a sense, 
invasion can then be propelled through intact EGFR 
signaling while preserving the EMT mechanism as driven 
by TGFß.
3. KLFs in stem cell transcriptional circuitries
Consequent to their structural properties and 
involvements in diverse cellular processes like 
proliferation, differentiation, apoptosis, EMT and 
motility, the activity of the KLF family shows a high 
degree of context dependence, related to both tissue and 
cellular backgrounds. A counterintuitive finding would 
be the absolute requirement of KLF4/Klf4 in somatic 
cell reprogramming [118,119]. It has been demonstrated 
that induction of adult somatic cells to pluripotent 
cells (induced pluripotent stem cells, iPSCs), with 
characteristics similar to embryonic stem cells (ESCs), 
can be managed through the introduction of KLF4 (human 
KLF4, mouse Klf4), SOX2 (human SOX2, mouse Sox2), 
OCT4 (human OCT4, mouse Oct4) and c-Myc (MYC), 
also referred to as the Yamanaka factors. From this set of 
transcriptional regulators, c-Myc has been regarded the 
only dispensable factor, leading to a less efficient yet more 
specific induction process [120]. In these studies, adult 
fibroblasts, murine or human, are often used as a somatic 
source to be redirected to a pluripotent state. Klf4 has been 
proven necessary for both induction and maintenance of 
pluripotency and self renewal. Interestingly, Klf4 is able to 
bind a distal enhancer of the central reprogramming factor 
Nanog [121], as well as its proximal promoter element 
[122,123]. Moreover, a mechanism of redundancy between 
different Klfs has been revealed in the maintenance of self 
renewal capacity. Klf4, initially considered as dispensable 
for sustaining the stem cell state, acts in cooperation with 
Klf2 and Klf5 to regulate the expression of Nanog through 
its distal enhancer element [121]. Only the coordinated 
and simultaneous depletion of Klf2, Klf4 and Klf5 drives 
ESCs into differentiation, indicating an important function 
of these Klfs in phenotype maintenance of embryonic/
induced stem cells. In addition, it was noted that forced 
Fig 4: Functional duality in promotion or inhibition (red cross) of invasion by KLF4 and KLF5 as dictated by 
contextual and microenvironmental conditions. Upstream and downstream interactions are indicated left and right to the KLF 
symbol respectively, added with experimental modalities and associated references per finding. CRC colorectal carcinoma, HNSCC head 
and neck squamous cell carcinoma, NSCLC non-small cell lung cancer, SC subcutaneous, SCC squamous cell carcinoma, SCID severe 
combined immunodeficient, TW transwell. * primary cultures.  
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downregulation of Klf2, Klf4 and Klf5 gave rise to cells 
solely expressing typical ectodermal, and not endodermal, 
markers (Fgf5, Nes, Cxcl12), suggesting downregulation 
of lineage specific genes by certain Klfs. 
Apart from the identified redundancy, Klf5 by itself 
was shown to exhibit specific functions in the commitment 
of ESCs to an undifferentiated state. Chromatin 
immunoprecipitation experiments demonstrated binding 
of Klf5 on the promoters of both Nanog and Oct4, and 
vice versa. Nanog cis-regulatory elements were detected 
in the Klf5 genomic region, indicating a feedback loop in 
ESCs [124]. Klf5 was found to act independently of Klf4, 
underlining its potential importance as a sole factor in 
maintaining the ESC state. Elimination of Klf5 impaired 
maintenance of the undifferentiated state of ESCs and 
induced the expression of several early differentiation 
markers. This effect was due to a deregulation of at least 
eight genes, targeted by Klf5, that contributed to the 
maintenance of ESCs [125].
Another study uncovered the link between the 
induction of pluripotency and EMT. Inducing mouse 
embryonic fibroblasts (MEFs) towards a pluripotent 
state essentially implied a MET program in the early 
stage of reprogramming [28,126]. Fibroblasts, showing 
a mesenchymal phenotype and expressing high levels 
of Snai1, needed the introduction of Klf4 to activate 
the epithelial marker E-cadherin (Fig 5). Repression of 
mesenchymal markers (Snai1, Fn1, Vim) is mediated 
by Sox2 and Oct4. The early and temporary transition 
to an epithelial-like state showed a prerequisite for 
successful reprogramming of fibroblasts to iPSCs. As 
mammary epithelial cells highly express endogenous 
Klf4 and the initial MET step thus becoming obsolete, 
the authors showed that reprogramming could be 
performed by introducing only Sox2 and Oct4. It was 
therefore postulated that epithelial cells are more 
amenable to somatic cell reprogramming than their 
fibroblastic counterparts [127]. Indeed, previous research 
revealed significantly higher efficiencies using primary 
keratinocytes instead of fibroblasts [128,129].
Recently, another approach was applied to 
increase reprogramming efficiencies. By performing 
sequential, rather than simultaneous introduction of the 
reprogramming factors, Liu and colleagues obtained a 
significantly higher yield of iPSCs [130]. The sequential 
introduction of the Yamanaka factors, starting with Klf4 
and Oct4, then Myc and finally Sox2 revealed an EMT-
MET program in the early phase of reprogramming. Oct4 
and Sox2 are known to stimulate, respectively inhibit the 
expression of Snai2, a mediator of EMT. Introducing 
Sox2 at a later stage during reprogramming allows Oct4 
to regulate an EMT step, hereby possibly homogenizing 
Fig 5: Overview of transitions between cell states and associated actions or counteractions by KLFs. The center field 
represents somatic cells, distributed in an epithelial (left) and a mesenchymal section (right) according to their respective properties. The 
outer field (grey) represents the stem cell state, divided into a pluripotent area (dark grey, left) and a general stem cell area (light grey, right) 
containing the CSC compartment. The iPSC reprogramming route departs from the somatic fibroblast through the “hypermesenchymal” 
state via an “epithelial-like” state to iPSC. Dotted arrows indicate putative actions.  
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the fibroblastic cell population to a “hyper-mesenchymal” 
state [131]. Klf4 activates Cdh1 transcription, eventually 
leading to the subsequent MET step, which is enhanced 
by the later introduction of Sox2 with a blocking effect on 
Snai2 [130]. Yet, driving Cdh1 expression is not the only 
function of Klf4 as forced expression of Cdh1 without 
Klf4 introduction did not give rise to iPSCs. The early 
introduction of Klf4 may be necessitized by its downstream 
activity upon Nanog transcription, as described in murine 
ESCs, and its ability to prevent ESCs from ensuing a path 
to differentiation [123]. In a recent study, the heterogeneity 
among MEFs was considered as another possible cause of 
the usual poor yield of iPSCs. It was revealed that different 
MEF subpopulations, based on surface marker expression, 
showed different degrees of reprogrammability. The 
CD90-/Sca-1+ cell populations could be reprogrammed to 
a pluripotent state using only two of the Yamanaka factors, 
namely Oct4 combined with either Sox2 or Klf4. From 
this approach, a partial functional redundancy between 
Sox2 and Klf4 was derived. Moreover, with respect to 
the intra-population heterogeneity, the rate-limiting MET 
as observed previously during reprogramming, could be 
considered only one out of many possible transient stages 
in a cell between a somatic and embryonic state [132].  
4. Context dependence and redundancy: lessons 
from proliferation
Certain studies yielded evidence for pro-tumoral 
effects, others for tumor suppressing effects by the same 
KLF member (Fig 4). Such duality has been demonstrated 
for the role of KLF4 in the regulation of cell proliferation 
[94]. In an untransformed cell, KLF4 decreased p53 
(TP53) levels by repressively binding a PE21 element 
located in the proximal promoter region of the TP53 gene. 
Simultaneously, KLF4 induced expression of CDKN1A 
leading to cell cycle arrest. The latter effect seemed 
dominant in untransformed cells, illustrating the tumor 
suppressor role associated with KLF4. Changing the cell’s 
genetic background by introducing an oncogenic RasV12 
allele not only abolished the cytostatic function of KLF4 
through bypassing CDKN1A induction, but switched it 
into an oncogenic effect, with KLF4 showing its dominant 
action on repressing TP53 and thus preventing apoptosis. 
It was concluded that the output mediated by KLF4 was 
dependent on the genetic background. 
This phenomenon is reminiscent of the dual activity 
of TGFß signaling on tumor propagation, where TGFß 
was reported to act as a tumor suppressor in early-stage 
cancers, and as an oncogene in progressive disease 
[94,133]. Remarkably, both the TGFß pathway and KLF4 
seem to converge on CDKN1A which, on its turn, acts 
as a gatekeeper preventing oncogenic transformation 
[94]. KLF5, a transcriptional opponent of KLF4  and 
a driver of proliferation in intestinal cells [41], was 
shown to be a key factor in TGFß-mediated inhibition 
of proliferation. In unstimulated keratinocytes (HaCaT 
epidermal epithelial cell line), KLF5 activated cell cycle 
progression and proliferation by blocking the cell cycle 
inhibitor CDKN2B (p15) [134]. On the other hand, in 
the presence of TGFß1, KLF5 became a coactivator in 
TGFß-induced expression of CDKN2B. It was revealed 
that p300/CBP (CREB-binding protein, CREBBP), 
initially recruited to the Smad2/3/4 complex upon TGFß 
treatment, reversed the function of KLF5 by acetylation. 
In its acetylated state, KLF5 was able to bind three sites 
in the proximal region of the CDKN2B promoter and 
activate transcription. Contextual modulation of KLF5 
function was also found in its interaction with MYC, a 
proto-oncogene with proliferation-promoting activity. In 
similar experiments with keratinocytes, KLF5 stimulated 
MYC transcription through binding of both a KLF5-
binding element (KBE) and a TGFß-inhibitory element 
(TIE) in the proximal promoter region of MYC, thus 
confirming the activating effect on proliferation [135]. 
Conversely, when TGFß was applied to induce inhibition 
of proliferation, binding to KBE decreased significantly 
as KLF5 was recruited to the TIE sequence by TGFß in 
order to block MYC transcription. These results strongly 
point to the reversibility of KLF transcription function as a 
tool for balancing between proliferation and differentiation 
in the maintenance of epithelial homeostasis. This model 
adds a dimension to the conventional view of changing the 
levels of different transcription factors in order to mediate 
opposing outcomes. The dependency of KLF5-mediated 
effects on cellular backgrounds has been further illustrated 
in intestinal epithelial cells. Ectopic overexpression of 
KLF5 indeed stimulated proliferation of normal intestinal 
epithelium through activation of CCND1, yet in colon 
cancer cells, proliferation and colony formation capacity 
were reduced through failure of KLF5 to induce CCND1 
[42]. This tumor suppressing role of KLF5 has been 
suggested in clinical breast [136] and prostate carcinomas 
[137], where loss of KLF5 was observed when compared 
to normal tissue counterparts. 
Despite being derived mainly from processes related 
to proliferation, the identified mechanisms comprise 
molecular modifications that alter the function of the 
same transcription factor in a context-dependent fashion. 
These alterations may also be present within an EMT- and/
or invasion-related context, mediating cancer progression 
to a metastatic state. The expression of different KLFs is 
often tissue-specific and existence of redundant subgroups 
within the KLF family is emerging [121,138]. Redundancy 
enables certain tissue-specific KLF family members to 
exert identical actions in different tissues where expression 
of companion KLFs is limited or absent. Moreover, due to 
their highly similar cis-acting properties combined with 
trans-acting variability, redundant KLFs may compete 
with one another for an identical cognate DNA binding site 
and impose opposite effects on transcription. KLF4 and 
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KLF5 are known for binding site competition as well as 
for transcriptional autoregulation. KLF4 activates its own 
transcription, thus sustaining its presence, and explicitly 
blocks cell cycle progression [139]. KLF5, a stimulator 
of proliferation, represses the auto-activation loop of 
KLF4. However, KLF4 is able to inhibit transcription of 
KLF5 in order to maintain a dominant role in preventing 
proliferation [41]. In the intestine, differential expression 
of both these KLFs was demonstrated between crypt 
and villus cells. Crypt cells with an intense proliferative 
activity indeed expressed KLF5 at higher levels, whereas 
terminally differentiated villus cells showed the opposite, 
with higher expression of KLF4. This implies a KLF4/
KLF5 balance shift occurring during the movement 
of cells from the crypts towards the villi in intestinal 
tissue homeostasis. Similar implications for KLF4 in 
terminal epithelial differentiation have been found earlier 
in epidermal epithelial cells [140]. This mechanism is 
engaged by two related KLFs in close competition to yield 
different cellular outcomes, without chemical modulation.
5. KLFs in metastasis: attempt to an integrated 
view
The epithelial state is profoundly influenced by 
the KLF family of transcription factors, based on studies 
using a diverse set of cell types and tissues. As their 
presence and activity has been demonstrated in different 
epithelial tissues and derived carcinoma types, added with 
their fundamental role in somatic reprogramming and 
its associated transit through an epithelial phase (Fig 5), 
KLFs are thoroughly embedded in a regulatory system 
that participates in cell fate determination. Nevertheless, 
the integration of the various mechanisms that have been 
identified remains a complex challenge.
It has been agreed that the dissemination of 
cancer cells from the primary site to distant organs and 
the subsequent successful colonization leading to overt 
metastasis, requires a significant degree of cellular 
plasticity [141]. 
The EMT/MET program and the cancer “stemness” 
program, provide a dynamic framework in which different 
KLFs appear to contribute a significant role. The presence 
of both E-boxes as CACCC elements in the promoters of 
EMT genes allows Krüppel-like transcriptional regulators 
to participate in the EMT program, in parallel with the 
previously recognized zinc finger E-box binding and 
bHLH factors. Moreover, it has been demonstrated that 
cellular state changes are mediated, in part, by specific 
KLFs in a time-dependent manner. It has become clear 
that the functioning of KLFs, individually and in concert, 
is dependent of three main determinants:  (1) the tissue 
of origin, (2) the cellular genetic background (context) 
and (3) the surrounding microenvironment. The final 
output, as triggered by KLF transcription, will often be 
the result of the interplay between these three features. 
Furthermore, this also illustrates the intra- and inter-tumor 
heterogeneity that has increasingly been recognized in 
several epithelial cancer types [142]. Given the versatility 
of their functioning, the KLF circuitry seems to fit in this 
plasticity that provides a cancer cell with the ability to 
proceed to invasiveness and to overcome the multiple 
barriers towards metastasis.
KLF8 unambigously drives cancer cells into the 
mesenchymal state [27], hereby facilitating invasion. 
However, maintenance of this phenotype is unfavorable 
in the long term as ectopic survival requires a switch 
back to a more epithelial state resembling the primary 
tumor [143]. The contrasting findings regarding KLF4 
and KLF5 have been shown to originate from both the 
cellular and microenvironmental contexts. KLF4 has 
been reported to have a role in epithelial differentiation 
and inhibition of growth [29], and thus often becomes 
repressed in cancerous tissue. Interestingly, the presence 
of HGF in the proximity of cancer cells, triggers KLF4 
to inhibit CDH1 transcription [38]. In addition, by 
modulating splice factor expression, HGF mediated an 
intracellular shift from the tumor suppressor KLF6 to the 
pro-metastatic KLF6-SV1 ([54], see also Fig 2 and 5). 
These examples illustrate microenvironmental properties 
igniting invasion and metastasis. An altered genetic 
background, for example oncogenic Ras, can lead to 
phosphorylation by extracellular signal-regulated kinase 
(ERK), hereby inversing the functioning of particular 
KLFs. Within this context, KLF5 has been shown to lose 
its proliferation promoting effect that is typical for normal 
intestinal crypt cells [42]. A similar outcome was observed 
in normal keratinocytes under exposure to TGFß [134], 
indicating that Ras-transformed cells have acquired an 
intrinsic competence to modulate KLF function whereas 
normal cells need the extrinsic influence from the TGFß 
cytokine. As KLF5 also directly activates transcription 
of CDH1, downregulation may indirectly play in favor 
of a progressive phenotype of certain cancer types, but 
not all. AR signaling was shown to activate CXCR4 
protein expression through KLF5 in prostate cancer cells, 
propelling chemotactic migration in response to CXCL12, 
a chemokine abundantly present in the microenvironment 
and specific sites of metastasis [104,105]. In the latter 
case, KLF5 becomes a tool to assist invasive behavior.
TGFß acts as a master regulatory cytokine, being 
able to manipulate transcriptional functions in early and 
advanced-stage cancers. Within this scope, TGFß has the 
potency to induce EMT, partly through KLF8 [67]. KLF10 
and KLF11 sustain the TGFß signaling node by inhibiting 
smad7 and supporting the smad2/3 complex formation. 
The recent association of low expression levels of KLF10 
with advanced disease in pancreatic cancer [74], may in 
part be explained by the repressive action of KLF10 on 
EGFR expression [117]. In a way, TGFß signaling may be 
maintained by KLF11, hereby driving an EMT program, 
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while downregulation of KLF10 favors the expression of 
EGFR, triggering other pro-invasive signaling cascades. 
KLF4 was reported as an opponent of TGFß-induced 
EMT due to its repression of SNAI2 [32]. However, as this 
repression is reciprocal, i.e. SNAI2 itself represses KLF4 
as well, a balance between both factors can determine 
a transit towards a mesenchymal state, with a positive 
feedback on expression of the central TGFß components, 
mediated by KLF4. Similarly, the extensively described 
tumor suppressor KLF6 antagonizes EMT, but activates 
transcription of TGFß ligand and receptors 1 and 2 [66]. 
In an EMT context, propelled by TGFß, KLF6 may 
play a supporting role, favoring cancer cell progression. 
Moreover, cancer cells with disabled TGFß machinery 
produce high levels of CXCL5 when confronted with 
persistent TGFß ligand, both in an autocrine and a 
paracrine fashion [83]. KLF4 is also known to activate 
CXCL5 transcription [82], corroborating the establishment 
of a chemotactic gradient that guides MDSC recruitment 
to the invasive front. As reported most recently, MDSCs 
induce stemness and tumorigenicity in proximal cancer 
cells through miR-101-mediated repression of C-terminal 
binding protein 2 (CtBP2), a corepressor of stemness core 
genes [144]. 
When considering the circuitries involving KLFs in 
cancer progression, their involvement in the establishment 
and maintenance of stem cell phenotypes must not be 
overlooked. KLF4, and KLF5, have a fundamental role in 
the reprogramming of somatic cells and the maintenance 
of self renewal capability. In this light, it might be 
speculated that these factors may become upregulated 
in a subset of cancer cells with stemness properties. 
This is reasonably supported by the upregulation of 
KLF4 in breast cancer stem cells as defined by marker 
expression, and the observed loss in bulky cancerous 
tissues. Furthermore, KLF4 is necessary in the adaptation 
of metastatic breast cancer cells in the brain niche [86]. On 
the other hand, EMT confers cancer cells with stem cell 
properties [145], a finding that apparently contrasts with 
the indispensable MET step as initiated by KLF4 during 
somatic reprogramming [146]. Nevertheless, in order to 
successfully reprogram cells towards a pluripotent state, 
KLF4 needs to be introduced at an early phase, probably 
in line with its ability to activate NANOG and OCT4 
expression, in parallel with CDH1 [121,122]. 
It must be noted, however, that migrating cancer 
cells exhibit EMT in combination with self renewal 
capabilities and anoikis resistance, thus traits of CSCs, 
yet without pluripotency. Logically, the latter is an 
unnecessary property as CSCs only need to recapitulate 
the original epithelial phenotype upon arrival at a distant 
organ site. Altogether, whether CSCs can be assigned a 
Fig 6: Hypothetic view on the plasticity of KLF expression as a contributor to cellular plasticity, shown from normal 
epithelium through different stages to metastasis. Putative expression levels of different KLFs vary depending on the requirements 
per phase. Dotted lines represent putative expression changes based on indicative findings, yet without reported direct evidence. HGF: 
upregulation of KLF4 under stimulation of HGF. EGFR: release of EGFR-inhibition through downregulation of KLF10.  In the metastatic 
setting, KLF4 became abundantly expressed in brain metastatic, but not bone metastatic cancer cells.
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pluripotent state remains unclear. These features have been 
merged in a concept involving so-called migrating cancer 
stem cells [147]. Metastasizing cancer cells should have 
obtained both EMT and CSC characteristics that enable 
them to locally invade the surrounding stroma, survive 
in the circulation and establish metastatic progeny. As 
NANOG represents the cornerstone transcription factor 
driving cells into a ground pluripotent state [148] and 
given that KLF4 and KLF5 are known NANOG inducers, 
a strict regulation of their expression would be needed 
to avoid passing irreversibly towards a pluripotent state. 
However, a certain degree of (transient) expression may 
be needed to instigate the potential of self renewal. As 
reported recently, MDSCs are able to contribute to the 
induction of stemness in cancer cells [144]. Pursuing 
this hypothetic path, colonization of the metastatic site 
de facto implies proliferation and, therefore, may require 
downregulation of KLF5 in Ras-transformed cancer cells. 
In certain metastatic niches, this may also be the case for 
KLF4, with the preliminary exception for the cerebral 
tissue environment [86]. As the survival of metastasized 
cancer cells is dependent on the expression of ID genes 
[58], KLF17 may need to remain downregulated as well 
in order to maintain the released repression of ID1 [55] 
(Fig 6).         
We wish to illustrate the plasticity of KLFs in their 
upstream regulation and their subsequent downstream 
effects on cellular plasticity as proposed for the 
progression of cancer to metastatic disease (Fig 4 – 6). This 
also reflects the potential suitability of KLFs to be used 
as markers participating in cancer phenotype definition 
and adding to the dissection of inter-tumor heterogeneity. 
As stated recently, future therapeutic approaches against 
cancers in a metastatic or metastasizing state, will most 
probably need to comprise a cocktail of compounds 
interacting with various processes, in an individually 
tailored strategy [141]. An activity profile containing 
KLFs and downstream target genes may indeed prove 
to substantially contribute to the individual definition of 
cancer characteristics at different stages. Furthermore, the 
gene pool downstream of KLF transcription factors can 
hide novel invasion and metastasis suppressor genes that 
may be amenable as potential therapeutic targets.
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